세리나 테라퓨틱스(SER)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.80 (-1.75%), 시가총액 $0.03B, 52주 범위 $1.28 ~ $6.18.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 20
세리나 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
세리나 테라퓨틱스의 현재 주가는 $2.80 (-1.75%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
세리나 테라퓨틱스의 시가총액은 약 $0.03B입니다.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment o